William Chase - AbbVie Executive Vice President CFO
| 4AB Stock | EUR 159.44 2.56 1.63% |
President
Mr. William J. Chase serves as Executive Vice President Finance and Administration of the Company. He served as Abbott Vice President, Licensing and Acquisitions from 2010 to 2012, as Vice President, Treasurer from 2007 to 2010, and as Divisional Vice President, Controller of Abbott International from 2004 to 2007. Mr. Chase joined Abbott in 1989. since 2018.
| Age | 50 |
| Tenure | 6 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0991 % which means that it generated a profit of $0.0991 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7239 %, meaning that it generated $0.7239 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Michael Harrington | Eli Lilly and | 53 | |
| Darren Carroll | Eli Lilly and | N/A | |
| Melissa Barnes | Eli Lilly and | 47 | |
| Susan Mahony | Eli Lilly and | 51 | |
| Leigh Pusey | Eli Lilly and | 60 | |
| Enrique Conterno | Eli Lilly and | 49 | |
| Joshua Smiley | Eli Lilly and | 47 | |
| David Ricks | Eli Lilly and | 55 | |
| Jan Lundberg | Eli Lilly and | 62 | |
| Stephen Fry | Eli Lilly and | 50 | |
| Maria Crowe | Eli Lilly and | 55 | |
| Barton Peterson | Eli Lilly and | 57 | |
| Fionnuala Walsh | Eli Lilly and | 56 | |
| Alfonso Zulueta | Eli Lilly and | 53 | |
| Jeffrey Simmons | Eli Lilly and | 48 | |
| Derica Rice | Eli Lilly and | 51 | |
Management Performance
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Alban, Executive Vice President - Commercial Operations | ||
| Robert Michael, Vice President Controller | ||
| Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President CFO | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, Gen VP | ||
| Azita SalekiGerhardt, Senior Vice President - Operations | ||
| Scott Reents, VP CFO | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman of the Board, CEO | ||
| Brian Durkin, Vice President Controller | ||
| Thomas Hurwich, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Thomas Hudson, VP Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, VP Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Timothy Richmond, Senior Vice President - Human Resources | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive Vice President - Business Development, External Affairs, General Counsel | ||
| Roy Roberts, Independent Director | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 331.38 B | |||
| Shares Outstanding | 1.77 B | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 71.51 % | |||
| Price To Earning | 22.27 X | |||
| Price To Book | 18.07 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AbbVie in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AbbVie's short interest history, or implied volatility extrapolated from AbbVie options trading.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |